Objective: A phase I double-blind clinical trial was conducted to evaluate the effects of a high oral dose of soy isoflavones administered daily for 84 days to healthy postmenopausal women. Principal outcome measures included DNA damage, apoptosis, and changes indicative of estrogenic stimulation.
M any women supplement their diets with soy isoflavones because case-control studies conducted in China 1 and in Asian Americans, 2, 3 as well as in a prospective cohort study from Japan 4 showed an inverse relationship between soy intake and breast cancer risk. The chemopreventive effects of soybeans and soy-containing foods may be related to their isoflavone content. 5/9 Daily intakes of 39 to 47 mg/day isoflavones have been reported in Japanese populations. 10, 11 In the United States, dietary consumption of soy isoflavones in the general population is much less than this amount (G5 mg/day), and diet supplements are being used to increase daily intake. These isoflavones exert multiple effects including estrogen receptor activation 12, 13 as well as antiestrogenic actions, 14 antioxidant activity, 14 inhibition of growth factor receptor signaling via tyrosine kinases, 15/18 induction of apoptosis, 19/22 induction of cell differentiation, 23 and inhibition of angiogenesis. 24 Some investigators reported that soy isoflavones, particularly genistein, caused gene damage. 25 Genistein induced mammalian topoisomerase II dependentYDNA cleavage in purified broken cell preparations 26 and at high doses induced the production of large numbers of micronuclei (a measure of chromosomal damage) in mouse splenocytes in culture. 27 However, our earlier study in men treated with high-dose soy isoflavones did not confirm this 28 ; there was no increase in double-stranded breaks in DNA. There is also significant concern that soy isoflavones have estrogenic actions that might increase proliferation in estrogen receptor (ER)Ypositive breast cancers. 29 Soy isoflavones bind to both ER-> and ER-A and are 1/1,000 as potent as estrogen in activating ER-> and one third as potent as estrogen for ER-A. 30 At this time, there is considerable controversy as to whether isoflavones are net estrogen agonists 13, 29, 31 or whether they act via antiestrogenic effects. 32 One possible explanation may have to do with variations among women in the capacity to form the isoflavone metabolite equol. 33, 34 Equol binds to both ER-> and ER-A and remains in the circulation longer than do genistein or daidzein. 33, 34 The capacity to form equol depends on colonization of the intestine with certain bacteria and occurs in approximately 20% to 35% of the Western adult population and 50% to 55% of the population living in Asian countries. 33 The objective of this study was to determine whether healthy postmenopausal women developed estrogenic effects, genotoxicity, or increased apoptosis when treated orally with a high-dose isoflavone mixture (70% unconjugated isoflavones containing genistein, daidzein, and glycitein) for 84 days. In addition, we determined whether women who produced the daidzein metabolite equol differed in these outcome markers from women who did not.
METHODS

Participants
Healthy nonobese postmenopausal women were recruited from the Research Triangle area of North Carolina by advertisements placed in local newspapers, mass informational e-mails, and flyers placed in strategic locations such as grocery stores and churches. Postmenopausal status was defined as having last spontaneous menstrual bleeding more than 12 months ago and follicle-stimulating hormone (FSH) greater than 30 mIU/mL (later amended to 27 mIU/mL as the laboratory method used for the analysis changed). Nonobese was defined as a body mass index less than 35 kg/m 2 . Women taking hormone/estrogen therapy or selective estrogenreceptor modulators within 3 months of enrollment or at high risk of breast cancer (5-year risk of Q1.9%) as assessed by the National Cancer Institute_s (NCI) Breast Cancer Risk Assessment Tool (http://bcra.nci.nih.gov) were excluded. Use of oral antibiotics within the 3 months before enrollment, supplements containing isoflavones within 1 month before enrollment, current tobacco use, or routine alcohol ingestion of more than two drinks per day were also reasons for exclusion. Before acceptance into this study, each volunteer_s health was verified by medical history, physical examination by a licensed medical doctor, screening laboratory tests, chest x-ray, and electrocardiogram. In addition, the women were required to furnish copies of negative mammograms and Pap smear reports dated within the past year.
Seventy-two women met eligibility criteria based on an initial telephone screen and were scheduled for a two-part screening appointment. Thirty-eight women met initial eligibility after screening, and 36 women were enrolled. One woman was terminated from the study due to FSH levels that were too low. Another two women completed the study, but their information was dropped because it was later determined that their prestudy mammograms were not normal. Three other women decided not to complete the study. One woman moved to another state, one stated that the study supplement made her irritable, and another claimed personal reasons for not completing the study. The remaining 30 women successfully completed the study. Demographic information on these women is presented in Table 1 .
The women provided written informed consent, and the study was conducted in accordance with the guidelines of the Institutional Review Board of the School of Medicine at the University of North Carolina (UNC) at Chapel Hill. We operated under an Investigational New Drug application (no. 54137) for the isoflavone preparation, which was obtained from the US Food and Drug Administration by the NCI for use in cancer prevention trials. Westat (Rockville, MS), the monitoring agency designated by the NCI, conducted a complete evaluation of study procedures and study event documentation.
Equol status
After eligibility was determined, all women ingested 473.2 mL of soy milk containing 50 mg of daidzein 33 to determine whether they were producers of the daidzein metabolite equol. After 18 hours, blood was collected, and serum equol was determined by Dr. Kenneth Setchell at Cincinnati Children_s Hospital Medical Center using high-pressure liquid chromatography mass spectrophotometry. 33, 34 Equol producers were defined as individuals with plasma equol concentrations greater than 20 Kg/L; nonequol producers were those with equol concentrations less than 10 Kg/L. Individuals with intermediate equol concentrations (Q10 Kg/L to e20 Kg/L) were to be excluded from the study; however, reanalysis of plasma samples revealed that one included woman was an intermediate producer. Intermediate producer (n = 1) Nonproducers (n = 13) Placebo (n = 12) 53.50 T 1.06 25.23 T 1.02 White (n = 10) Producers (n = 2) African American (n = 1) Nonproducers (n = 10) Asian American (n = 1) Race was determined by woman report. Equol producer status was determined using a soy milk (containing 50 mg of daidzein) feeding challenge. After 18 hours, blood was collected and serum equol was determined. Equol producers were defined as individuals with plasma equol concentrations greater than 20 Kg/L and nonequol producers as those with equol concentrations less than 10 Kg/L. Individuals with equol concentrations greater than 10 Kg/L to less than 20 Kg/L were defined as intermediate producers. BMI, body mass index.
Isoflavone formulation and dose
Protein Technologies International (PTI; St. Louis, MO), via the NCI, provided hard gelatin capsules that contained 70% or more of active substance as total unconjugated isoflavones (PTI G-2535 unconjugated isoflavonesY70). Isoflavones were produced under good manufacturing practices guidelines. University Pharmaceuticals of Maryland Incorporated (Baltimore, MD) formulated each capsule to contain 150 mg genistein activity. The composition of PTI G-2535 capsules (lot #UPM 9809-021) used in this clinical study was as follows: genistein 139.5 mg per capsule, daidzein 74 mg per capsule, and glycitein 11 mg per capsule. Two laboratories (Ralston Analytical Laboratories, St. Louis, MO; Sigma Chemical Laboratories, St. Louis, MO) independently analyzed isoflavone composition and concentrations. The preparation was stable at 40-C and 70-C for at least 6 months and at 25-C for 3 years (assays performed at University Pharmaceuticals of Maryland, Inc.). The placebo capsules were identical in size and color and contained excipients from the active formulation.
Study design
The study was conducted at the UNC General Clinical Research Center. On day 1 (prestudy drug), blood was drawn from the antecubital vein for prestudy determinations and stratified randomization (based on equol producer vs nonproducer status) was then used to assign the eligible women to active or placebo groups.
The active group (n = 18) received four capsules of dietary supplement PTI G-2535 (containing approximately 600 mg of genistein activity per day, approximately 10 times the dose conventionally used in diet supplements, and half this much daidzein) divided into two equal daily doses. The placebo group (n = 12) received the same number of placebo capsules. Participants self-administered the capsules with food both in the morning and in the evening for 84 days. To effectively monitor genistein concentrations, women were instructed not to consume diets containing more than 20 mg of genistein per day while enrolled in the study. Most women chose to abstain from soy altogether during their study participation. Follow-up visits were conducted on days 2, 7, 14, 28, 56, 84, and 112.
Monitoring of compliance and safety
Compliance was determined using capsule counts and total plasma genistein concentrations (blood sample drawn before the next dose in the morning on days 2, 7, 14, 28, 56, and 84). Plasma was analyzed for total genistein using highpressure liquid chromatography as previously described 35 except that we used an electrochemical detector (ESA Inc., Chelmsford, MA). We used trough genistein concentrations to detect individuals who accumulated genistein on the treatment and reduced the administered dose by 50% if the trough concentration exceeded 10,000 ng/mL (this level is based on the highest trough level [7300 ng/mL] seen in a previous study, 28 with a 33% margin added). All women were followed until 112 days after initiation of the study, 28 days after cessation of treatment.
Treatment toxicity was monitored with a panel of blood tests collected on days 1, 14, 28, 84, and 112, consisting of a complete blood count, blood urea nitrogen/creatinine ratio, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, F-glutamyl transferase, amylase, lipase, and triglycerides. An additional toxicity panel consisting of electrolytes, calcium, magnesium, phosphorus, lactate dehydrogenase, albumin, uric acid, total bilirubin, fibrinogen, prothrombin time, partial prothrombin time, thyroxine (T 4 ), thyroid-stimulating hormone, triiodothyronine uptake, and free thyroxine index was measured on days 1, 28, 84, and 112. Finally, blood pressure measurements were taken on days 1, 2, 7, 14, 28, 56, 84, and 112.
Per the regulations set forth by the UNC Institutional Review Board, all adverse events were classified by the study physician as mild, moderate, or serious and were graded according to the NCI_s Common Toxicity Criteria. Moreover, the study physician deemed these events (1) not or unlikely to be related to the study, (2) unknown, or (3) probably or definitely related to the study using her best clinical judgment. Specifically, if the adverse event was anticipated based on our previous results or in the published literature and was temporally related to isoflavone treatment, then it was deemed as probably study related. If the association of the event with isoflavone treatment was not conclusively related, but could not be ruled out, then the attribution of the event to the isoflavone treatment was deemed as unknown. Events that were clearly unrelated to isoflavone treatment (eg, events of known causes or events that temporally preceded the first isoflavone dose) were deemed as unlikely to be study related. All women in whom adverse events occurred were followed according to good clinical practice guidelines until resolution of the events.
Assessment of estrogenic/antiestrogenic effects
Estrogenic/antiestrogenic effects of isoflavones were measured using a self-report questionnaire covering menopausal side effects (including hot flashes, chest pain, shortness of breath, leg cramps or swelling, breast tenderness, breast enlargement, changes in sex drive, nausea, and vomiting) and by measuring serum concentrations of estrogen, FSH, luteinizing hormone, and sex hormoneYbinding globulin on days 1, 84, and 112. Attempts were made to obtain endometrial biopsy samples from all women pre-and postdose, but we were unable to collect sufficient material to assess the estrogen responsiveness of this tissue.
Assessment of genotoxicity and apoptosis
The potential of genistein to induce DNA damage was assessed via COMET assay in lymphocytes collected on days 1 and 84. This result was complemented by apurinic/ apyrimidinic (AP) sites assay in lymphocytes on the same days. Changes in apoptosis were evaluated via terminal deoxynucleotidyl transferaseYmediated dUTP nick end labeling (TUNEL) and caspase-3 activation assays conducted on lymphocytes collected on days 1 and 84.
Peripheral lymphocytes were isolated from blood using Ficoll-Hypaque gradient in evacuated tubes with sodium citrate (Vacutainer CPT; Becton Dickinson, Franklin Lakes, NJ) according to manufacturer_s instructions. 36, 37 Single-cell gel electrophoresis (COMET) was performed as described previously 38/40 ; this assay detects changes in DNA migration caused by strand breaks, alkaline labile sites, or transient repair sites. Lymphocytes were sandwiched between 0.5% regular agarose solution (Fisher, Fair Lawn, NJ) and 0.5% Low Melting Point Agarose (37-C; Fisher). The resulting slides were placed into cold, freshly made lysis solution (10 mmol/L Tris base, pH 10, 2.5 mol/L NaCl, 100 mmol/L ethylenediamine tetraacetic acid, 1% sodium sarcosinate, 10% dimethylsulfoxide, and 1% Triton X-100). Slides were placed in the refrigerator for a minimum of 1 hour and then pretreated for 20 minutes in electrophoresis buffer (300 mmol/L NaOH, 1 mmol/L ethylenediamine tetraacetic acid, pH 13) for 20 minutes. Electrophoresis was performed at 25 V and 300 mA for 20 minutes. After electrophoresis, slides were incubated three times for 5 minutes in neutralization buffer (0.4 mol/L Tris-HCl, pH 7.5), washed with methanol, and stained with ethidium bromide (20 Kg/mL; Sigma-Aldrich). For visualization of DNA damage, observations were made at Â400 magnification using an Olympus AX70 fluorescent microscope (Olympus Corporation, Lake Success, NY). Typically, 100 cells were analyzed per sample time point using cell image analysis software (Scion Corporation, Frederick, MD), and the COMET tail moment was calculated using a program in the NIH Image Analysis Macro language (National Technology Information Service, Springfield, VA).
The number of AP sites in genomic DNA from lymphocytes was quantified using a slot-blot method in which an aldehyde reactive probe was reacted with the aldehydic group of ring-opened AP sites, as previously published. 41 The formation of AP sites can lead to the induction of base substitution mutations or inhibition of DNA replication. 42 We measured DNA fragmentation in lymphocytes by TUNEL using an ApopTag in Situ Apoptosis Detection Kit (Chemicon International, Temecula, CA). Lymphocytes were fixed in 2% paraformaldehyde and suspended on a silanized microscope slide by cytospin. After fixation, the slides were stained with diaminobenzidine-peroxidase, and the nuclei were counterstained with 0.5% methyl green. The slides were mounted, and the percentage of TUNEL-positive cells was counted by light microscopy. At least 200 total cells were counted for each data point, and the amount was expressed as a percentage. We also assessed apoptosis using the Signal Stain Cleaved Caspase-3 (Asp175) IHC Detection Kit (Cell Signaling Technology, Danvers, MA). Briefly, this method detects endogenous levels of the large fragment (17/19 kd) of activated caspase-3 resulting from cleavage adjacent to Asp175. Lymphocytes were fixed in 2% paraformaldehyde and suspended on a silanized microscope slide by cytospin. Slides were incubated with prediluted cleaved caspase-3 (Asp175) antibody, which is bound by biotinylated sec-ondary antibody. Avidin DH and horseradish peroxidase were complexed by mixing defined amounts before use, and the mixture subsequently was used to bind the secondary antibody. The macromolecular complex was localized by incubation with NovaRed enzyme substrate, and the positive cells were counted by light microscopy (at least 200 cells for each data point).
Statistical analysis
To examine the effect of treatment group (active or placebo) and time on trough plasma genistein concentrations, a repeated-measures regression model was fit and various correlation structures were examined to take into account the fact that measures over time on the same person will be correlated. An unstructured correlation ultimately proved best. Treatment group and time as well as a treatment group Â time interaction term were included in the model.
Descriptive and inferential statistical analyses were performed to look for trends that would point to differences in estrogenic effects, clinical laboratory tests, blood pressure, genotoxicity, and apoptosis. Nonstratified (active vs placebo) and stratified (active equol producers vs active nonequol producers) data were studied. Descriptive statistics (n, mean, and SE) were calculated for the measurements collected on days 1 and 84 for the control and treatment groups and for the treated equol producer and nonequol producer groups. A permutation test was used to detect any differences in the mean change from day 1 to day 84 in the continuous response variables between groups (treated vs placebo and treated producers vs treated nonproducers) and for the compared mean between groups on days 1 and 84. Fisher_s exact test was used to detect any differences in the proportion of women who experienced side effects between the two groups. All analyses requiring a permutation test were performed using StatXact 4 (1989/1999, CYTEL Software Corporation, Cambridge, MA). All analyses using Fisher_s exact test were performed using SAS package version 9.1 (SAS Institute, Cary, NC). Based on COMET assay data (means and SDs) observed in our last study of isoflavone supplementation in men with prostate cancer, 28 the current study had 80% power to detect a mean difference of 0.43 in COMET tail moment between the supplemented and control groups. A two-sided significance level of 0.05 was used for all statistical tests. Table 1 . The mean age of women in the active group was 56.8 years and was 53.5 years in the placebo group. The mean body mass index of women in the active group was 26.2 and was 25.2 in the placebo group. The demographic profile for all the women collectively who completed the study was 86.7% white, 10.0% African American, and 3.3% (one woman) Asian American.
RESULTS
Demographic information on the women enrolled in the study is presented in
Equol producers versus non-equol producers
Among the 30 volunteers completing the study, there were six equol producers (20%; range, 21.8/46.6 ng/mL) and 23 nonproducers (80%; range, 0/8.5 ng/mL; Table 1 ). Of these, four were assigned to the active group and two were assigned to the placebo group. One woman was an intermediate producer (12.9 ng/mL) and was assigned to the active group. Because the number of equol producers was so small, results for producers and nonproducers were pooled. However, a cautious comparison of results seen in producers relative to nonproducers in the active group is presented at the end of Bresults.[
Trough genistein levels
Two women in the active treatment group had trough genistein concentrations that measured above the 10,000-ng/mL cutoff and thus had their daily dose halved as a result. A third woman in the active treatment group had her daily dose halved on day 2 because she had a low body weight and her trough genistein concentration measured close to 10,000 ng/mL on day 2. All women in the active group (n = 18) had measurable trough genistein concentrations at every follow-up study visit; the mean trough level during the treatment phase (through day 84) was 3,103 ng/mL. The mean trough genistein concentration among the 12 women in the placebo group was 11 ng/mL. Genistein trough levels (means and SEs) for each follow-up study visit are given in Table 2 .
Adverse events and safety data
A summary of all adverse events, judged to be probably or possibly related to soy isoflavone administration, is presented in Table 3 . (Note: women were monitored during the entire study for safety reasons, and data were collected for each study day, but the statistical analysis was made only for days 1 (baseline) and 84 (end of treatment) to determine the significant changes that may have occurred during the study.)
Analysis of the laboratory clinical measurements showed no significant change in the mean difference on day 84 from day 1, when comparing placebo and active groups. One woman, receiving placebo, experienced a grade 1 asymptomatic elevation in thyroid-stimulating hormone (4.74 KU/mL; reference range, 0.46/4.68 KU/mL) on day 28 that returned to normal by the next visit. This same woman had a decreased T 4 (5.3 Kg/dL; reference range. 5.5/11.0 Kg/dL) measurement on day 84. Further investigations made by her primary care physician showed normal thyroid indices. Isolated decreases in T 4 (not graded) occurred in four other women, one receiving active treatment (5.0 Kg/dL; reference range, 5.5/11.0 Kg/dL) and three receiving placebo (5.1 Kg/dL, 5.1 Kg/dL, and 5. 2 Kg/dL; reference range, 5.5/11.0 Kg/dL). By the end of the study, the T 4 values were normal in all women.
Other thyroid indices for these four women were within normal limits at all measurement points. At no time did any of the five women who experienced out-of-reference-range thyroid indices complain of any of the symptoms of hypothyroidism. Measurements made at all other study visits were within the normal range. One treated woman experienced one transient grade 1 elevation of aspartate aminotransferase (44 U/L; reference range, 14/38 U/L) on study day 28 that was deemed possibly related to study drug. This same woman had one episode of elevated triglycerides (340 mg/dL; upper limit of normal = 300 mg/dL) on study day 14 that met grade 1 criteria and was judged to be possibly related to study drug. One woman in the placebo group experienced one episode of grade 1 elevation in amylase (132 U/L; reference range, 30/110 U/L) on day 14, which was deemed unlikely to be related to study drug.
Two women in the active group experienced intermittent episodes of increased blood pressure (148/70 mm Hg; 158/98 mm Hg) that were judged to be possibly related to taking the study drug (Table 3 ). When statistical analysis was performed, no significant changes in mean systolic or diastolic blood pressure were noted (Table 4 ).
Estrogenic/antiestrogenic effects
There were no clinically significant changes in estrogenic/ antiestrogenic laboratory measurements (estrogen, FSH, 6 3 Hot flashes (decreased intensity) 1 1 Increased breast size or tenderness 2 0 Participants were asked to report any side effects noticed during their study participation. AST, aspartate aminotransferase; FSH, follicle-stimulating hormone; LH, luteinizing hormone; TSH, thyroid-stimulating hormone; T 4 , thyroxine.
luteinizing hormone, or sex hormoneYbinding globulin) (Table 4 ) between the groups. One woman receiving placebo experienced decreased FSH (11.0 mIU/L; reference range, 21.5/131 mIU/L) and luteinizing hormone (6.2 mIU/L; reference range, 13.1/86.5 mIU/L) levels on day 84. These levels were within the normal range when measured on day 112. Another woman receiving placebo had increased estrogen on day 1 (25 pg/mL; reference range, 5-38 pg/mL), which returned to normal during the study and increased again on day 112 (60 pg/mL; reference range, 5-38 pg/mL). Her estrogen value was normal when rechecked on day 133. All three laboratory abnormalities were considered adverse events that were possibly related to the study drug (Table 3) .
Information on estrogenic effects of soy isoflavones was also assayed by a self-report instrument that asked about hot flashes, breast changes, and other menopausal symptoms (Table 3 ). Throughout the course of the study, 8 of 18 (44%) women in the active group reported estrogenic or antiestrogenic effects, three fourths of these being increases in severity or frequency of hot flashes. In the placebo group, over the whole course of the study, 4 of the 12 (33%) women reported estrogenic or antiestrogenic effects, three fourths of these being increases in frequency of hot flashes. To assess effects on hot flashes after prolonged soy treatment, a statistical analysis of all women experiencing hot flashes between study days 56 and 84 was performed. During this period, 50% (6 of 12) of the women receiving placebo reported increased hot flash frequency, whereas 17% (3 of 18) of the women receiving isoflavones did so (proportions not significantly different). One woman receiving placebo reported increased breast tenderness on day 84.
Genotoxicity and apoptosis
The means for COMET, TUNEL, and caspase-3 assays were similar for the active and placebo groups at baseline (day 1) and day 84. The mean for AP site number on day 84 was higher in the placebo group (P G 0.05); however, there were no significant differences between the placebo and active groups in mean change in AP site number from day 1 to day 84 (Table 4 ).
Equol producer status: possible effects
A secondary aim of this study was to determine whether women who are equol producers have different responses to isoflavones than women who are not equol producers. Twenty percent (six women) of the women enrolled in the study were equol producers. This percentage is comparable with what has been reported in the literature. 33 The number of producers may have been slightly smaller in our study due to the small sample size and random variation. Despite these small numbers, we statistically analyzed the producers versus nonproducers from the active group to generate hypotheses about the impact of equol production status in response to isoflavone administration. Analysis of the laboratory clinical measurements showed no statistically significant difference in mean values on days 1 and 84. Means between the groups were comparable except that the neutrophil count on day 1 was significantly higher for treated nonproducers. There were no differences between groups in COMET, TUNEL, or AP site assay. However, activated caspase-3 was higher in treated producers on day 1 and between days 1 and 84, equol producers in the active group decreased caspase-3 activation, whereas nonproducers increased activation, although none of these results were statistically significant.
There was a significant difference between the nonproducers and producers of equol in the active group in the percentage of women who experienced hot flashes as reported on day 84. No women in the nonproducer group receiving isoflavones reported hot flashes, whereas 50% in the producer group reported hot flashes.
DISCUSSION
In a previous study in men with prostate cancer, we reported little toxicity or estrogenicity after 84 days of treatment with high-dose isoflavones. 28 However, as all these men had taken or were taking a stable course of hormone therapy as part of their cancer treatment, it was difficult to determine the relationship of any observed symptoms with isoflavone administration. In the same study, the potential genotoxicity of isoflavone administration also was examined. Overall, no changes in average COMET occurred over the course of the treatment. However, in three individuals, we observed increases in COMET, and in one of these individuals, we observed an increased micronucleus frequency. As this previous study was conducted in men who had cancer and who were potentially exposed to genotoxic drugs and treatments, it was difficult to definitively determine the relationship of isoflavones to the observed genotoxic effects. For this reason, in the present study, we administered high-dose isoflavones to healthy individuals at a daily dose that greatly exceeded (by approximately 10-fold) doses likely to be self-administered by those using dietary supplements.
As discussed earlier, several studies conducted in cell culture showed DNA damage and micronucleus formation after exposure to genistein. 25,26,43<46 In this study, we found no evidence of genotoxicity in the lymphocytes of the healthy women exposed to high doses of isoflavones. This suggests that short-term supplementation (84 days) with high doses of soy isoflavones is safe in postmenopausal women.
In previous studies, it was shown that genistein induced apoptosis in cells by inhibiting tyrosine kinase growth signaling. 22, 47, 48 Also, topoisomerase II, an enzyme involved in the relaxation and uncoiling of DNA (decatenation), is inhibited by genistein. 49 This process involves double-strand breaks followed by religation. 49, 50 We observed no significant changes in apoptosis as assessed by TUNEL for any of the groups in our study. Caspase-3 was not significantly different between placebo and treated groups. The fact that between days 1 and 84, equol producers in the active group decreased caspase-3 activation, whereas nonproducers increased activation (not statistically significant), however, suggests that equol itself may inhibit apoptosis or, alternatively, that the diversion of daidzein to form equol may lower the concentration of an active constituent or metabolite derived from isoflavones that induces apoptosis.
There was a trend toward lower incidence of hot flashes after 3 months in women receiving the soy isoflavones, but overall we cannot conclude that soy isoflavones will reduce symptoms associated with menopause if used in postmenopausal women as these self-reported symptoms are prone to reporter bias and placebo effects. The significant difference between the nonproducers and producers of equol in the active group in the percentage of women who experienced hot flashes as reported on day 84 suggests that equol production status may increase the antiestrogenic potential of soy isoflavones.
There were no clinically significant changes in hormone or hormone-related laboratory values that suggested estrogenic or antiestrogenic activity of isoflavones in postmenopausal women. This is an important observation because concerns about potential estrogenic activity of isoflavones has limited their use as a dietary supplement in women for fear that latent breast cancer cells might be stimulated to grow. 51 However, the lack of changes in hormone levels can only be taken as correlative and not as absolute evidence that soy isoflavones did not exhibit estrogenic activity in this sample of postmenopausal women. Unfortunately, the estrogenic potential of the soy isoflavones was not directly assessed in an estrogen-dependent tissue such as the vagina and uterus. Attempts were made to collect endometrial biopsy samples, but insufficient tissue was available to look at pathological or biochemical changes. Thus, any assessment of soy isoflavone estrogenicity must be interpreted with caution.
It is well-known that menopause is associated with a dramatic increase in prevalence of hypertension in women, and previous clinical and animal investigations have suggested that estrogen has a protective role against hypertension. However, some clinical trials have found contradictory results. 52 Conflicting evidence of the effects of soy isoflavones on blood pressure also has been reported 53 ; thus, we asked whether a very high dose of isoflavones would make a difference and establish a directional effect of soy on blood pressure. The results of our analysis suggest that 84 days of treatment with soy isoflavones did not result in appreciable changes in blood pressure.
CONCLUSIONS
In summary, these results suggest that unconjugated soy isoflavones are safe and well tolerated in healthy postmenopausal women at doses of 900 mg/day. Very few adverse events occurred, and the only drug-related adverse events were mild in severity. Although there has been considerable debate on the estrogenic potential of isoflavones, our study showed only very minimal effects. However, as narrow inclusion/exclusion criteria were chosen due to potential safety reasons related to treating postmenopausal women with very high doses of soy isoflavones, these results may not hold for all postmenopausal women. Equol could be an important modulator of soy isoflavones and larger studies on the effects of isoflavone supplementation in humans are warranted.
